^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Breast Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

    Excerpt:
    ...- Confirmed diagnosis of ER positive/Her2-negative breast cancer...
    Trial ID:
    MECCA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

    Excerpt:
    ...- ER-positive, node-negative or ER-positive Grade 1 or 2 node-positive breast cancer 5....
    Trial ID:
    NCT01439282
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Cancer Res Clin Oncol
    Title:

    Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort

    Published date:
    01/20/2021
    Excerpt:
    Retrospective study of consecutive MBC patients treated at University Hospitals Leuven starting capecitabine...Patients with DR, as compared to those without DR, were more likely oestrogen receptor (ER) positive (91.5% vs. 76.8%, p = 0.010)…
    DOI:
    10.1007/s00432-020-03487-1